本文選題：子宮頸癌 + HPV疫苗�。� 參考：《臨床與實驗病理學雜志》2017年09期

【摘要】：正子宮頸高級別上皮內(nèi)病變(CIN2-3)是起源于鱗柱交界(SCJ)的獨特細胞群。CK7作為鱗柱交界細胞群的免疫組化標志物,被應用于低級別上皮內(nèi)病變(即CIN1)的診斷。本實驗將一小部分可能進展為CIN2-3的病例分離出來,其余大多數(shù)CIN1病例不需要進一步干預治療。作者回顧性分析子宮頸CIN1組織中CK7的表達情況,材料來自HPV疫苗實驗中使用安慰劑的人群。免疫組化染色判讀:陰性、斑駁陽性、分層陽性(即上-下)及全層陽性。
[Abstract]:CIN2-3) is a unique cell group originated from SCJs. CK7 is used as an immunocytochemical marker of SCJs and is used in the diagnosis of low grade intraepithelial lesions (CIN1). In this study, a small number of cases that may progress to CIN2-3 were isolated, and most of the remaining CIN1 cases did not require further intervention. The authors retrospectively analyzed the expression of CK7 in cervical CIN1 tissues from people who used placebo in HPV vaccine trials. Immunohistochemical staining: negative, mottled positive, stratified positive (i.e. upper-lower) and the whole layer positive.
【作者單位】： 解放軍第180醫(yī)院病理科;解放軍福州總醫(yī)院病理科;
【分類號】：R737.33

【相似文獻】

相關期刊論文 前10條

1 姜志欣;吳玉t，

本文編號：1886709